Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-01-31
1997-02-25
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3154, A61K 31445
Patent
active
056059116
ABSTRACT:
Methods and compositions are disclosed for treating or preventing adverse CNS effects produced by NMDA receptor hypofunction (NRH), including hypofunction induced by NMDA antagonist drugs, and hypofunction occurring as a causative or aggravating factor in schizophrenia. One method of this invention comprises administering an alpha-2 adrenergic (.alpha.2) receptor agonist drug along with an NMDA antagonist drug. The NMDA antagonist drug exerts a primary benefit in reducing excitotoxic brain damage, alleviating neuropathic pain, or preventing or avoiding tolerance or addiction to various types of drugs. The .alpha.2 agonist drug acts as a secondary or "safener" drug, to prevent the neurotoxic side effects that would be caused by the NMDA antagonist in the absence of the safener drug. Another method disclosed herein involves the use of an .alpha.2 agonist drug, by itself, to combat a different and naturally-occurring form of NMDA receptor hypofunction which occurs as a causative or aggravating mechanism in people suffering from schizophrenia. Although .alpha.2 agonists are usually not effective in treating long-standing cases of chronic schizophrenia, where pathological changes in the brain have already reached or approached maximal levels, .alpha.2 agonists can be administered early in the illness, such as at the first signs of schizophrenic illness, and continuously or intermittently thereafter to prevent the development or worsening of pathological brain changes.
REFERENCES:
patent: 5034400 (1991-07-01), Olney
Farber, N. B., et al, "Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity," Biol Psychiatry 34: 119-121 (1993).
Freedman, R., et al, "Clonidine treatment of schizophrenia: Double-blind comparison to placebo and neuroleptic drugs," Acta Psych. Scand. 65: 35-40 (1982).
Jimerson, D. C., et al, "Preliminary trial of the noradrenergic agonist clonidine in psychiatric patients," Biol. Psychiatry 14: 45-57 (1980).
Ko, G. N., et al, "Alpha-2 adrenergic agonist binding in Schizophrenic brains," Psychopharmacology Bulletin 22: 1011-1016 (1986).
Olney, J. W., et al, "NMDA antagonist neurotoxicity: Mechanism and prevention," Science 254: 1515-1518 (1991).
Rogawski, M. A., "The NMDA receptor, NMDA antagonists, and epilepsy therapy: A status report," Drugs 44: 279-292 (1992).
Ruffolo, R. R., et al, "Pharmacologic and therapeutic applications of .alpha.2-adrenoceptor subtypes," Annu. Rev. Pharmacol. Toxicol. 32: 243-279 (1993).
Trendelenburg, A., et al, "Presynaptic a2 autoreceptors in brain cortex: .alpha.2D in the rat and .alpha.2A in the rabbit," Arch Pharmacol 348: 35-45 (1993).
Van Kammen, D. P., et al, "Clonidine treatment of schizophrenia: Can we predict treatment response?" Psychiatry Research 27: 297-311 (1989).
Olney et al, "NMDA Antagonists as Neurotherapeutic Drugs, Psychotogen, Neurotoxins, and Research Tools for Studying Schizophrenia", Neuropsychopharmacology 1995--vol. 13, No. 4, pp. 335-345.
Farber Nuri B.
Olney John W.
Kelly Patrick D.
Nutter Nathan M.
Washington University
LandOfFree
Use of alpha-2 adrenergic drugs to prevent adverse effects of NM does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of alpha-2 adrenergic drugs to prevent adverse effects of NM, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of alpha-2 adrenergic drugs to prevent adverse effects of NM will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1974179